Innovent Biologics, Inc.
1801.HKFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
1,225
Cost of Revenue
196
Gross Profit
1,029
Gross Margin
84.0%
Operating Income
-98
Operating Margin
-8.0%
Net Income
-12
Net Margin
-1.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-62
EBITDA Margin
-5.1%
2023
12/31/2023
Revenue
807
Cost of Revenue
235
Gross Profit
572
Gross Margin
70.9%
Operating Income
-218
Operating Margin
-27.1%
Net Income
-134
Net Margin
-16.6%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-86
EBITDA Margin
-10.6%
2022
12/31/2022
Revenue
592
Cost of Revenue
121
Gross Profit
471
Gross Margin
79.6%
Operating Income
-406
Operating Margin
-68.5%
Net Income
-283
Net Margin
-47.8%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-227
EBITDA Margin
-38.4%
2021
12/31/2021
Revenue
555
Cost of Revenue
74
Gross Profit
481
Gross Margin
86.6%
Operating Income
-351
Operating Margin
-63.3%
Net Income
-355
Net Margin
-63.9%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-309
EBITDA Margin
-55.6%
2020
12/31/2020
Revenue
500
Cost of Revenue
50
Gross Profit
449
Gross Margin
89.9%
Operating Income
-72
Operating Margin
-14.5%
Net Income
-130
Net Margin
-26.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
-92
EBITDA Margin
-18.3%